Bladder Cancer Coverage from Every Angle
Advertisement
Advertisement

Published Medical Literature

Radical Cystectomy for Bladder Cancer: Comparison of Surgical Techniques From Sweden
Case Report: Transurethral Resection for Osteosarcoma of the Bladder
Can Oxidative Stress–Related Genes Predict Outcomes for Patients With Bladder Cancer?
Update on Managing Bladder Cancer: An Evolving Landscape
Alternatives to Radical Cystectomy for Muscle-Invasive Urothelial Carcinoma: Clinical Considerations
TRIM38/GLUT1 Axis May Promote Bladder Cancer Tumorigenesis
Adding Nintedanib to Neoadjuvant Chemotherapy for Locally Advanced Bladder Cancer
Evaluating the Risk of BK Polyomavirus Infection During Childhood and Future Bladder Cancer
Seven-Gene Signature Risk Score: Predictive of Prognosis in Bladder Cancer?
Study Finds Disproportionate Racial and Ethnic Representation in Clinical Trials for Bladder Carcinoma
Can Tumor Morphology Predict Depth of Invasion in Bladder Cancer?
Early-Phase Study of Infigratinib Supports Further Work in Metastatic Urothelial Carcinoma
Predicting Recurrence in Bladder Cancer: Focus on Immune Profiles, DNA Methylation Alterations
Alternative to Intravesical Chemotherapy Under Study in Non–Muscle-Invasive Bladder Cancer
The Impact of Neoadjuvant Immunotherapy in Muscle-Invasive Bladder Cancer
Use of Cabozantinib Plus Nivolumab After Immunotherapy in Metastatic Urothelial Carcinoma
Is There a Link Between Bladder Cancer and Human Papillomavirus?
Long Non-Coding RNA: Potential Therapeutic Target in Bladder Cancer?
Predicting Prognosis in Bladder Cancer: Focus on Unfolded Protein Response–Related Gene Signature
Use of Toripalimab in the Second-Line Setting for Advanced Urothelial Carcinoma
Newly Developed and Validated Prognostic Signature for Patients With Bladder Cancer
Effect of Smoking-Related Lung Disease on Bladder Urothelial Carcinoma Survival
Pancreaticoduodenectomy for Metastasized Bladder Cancer: Case Report
Preclinical Study of Tumor Microenvironment in Bladder Cancer Offers Clues to Causes of Chemoresistance
Five-Gene Score Model Under Study in Predicting Outcomes in Bladder Cancer
Evaluating Risk-Aligned Bladder Cancer Surveillance Practices
Metastatic Urothelial Cancer: Does Prior Treatment Hinder the Effectiveness of Pembrolizumab Therapy?
Cisplatin Versus Carboplatin: Overall Survival in Dutch Cohort Study of Metastatic Bladder Cancer
Treatment of Bladder Cancer After Platinum and PD-1/L1 Inhibitor Therapy: Real-World Outcomes
Rare Combination of Fibroepithelial Polyp and Kidney Cancer in a Patient With Bladder Cancer
Can Novel ATR Inhibitor Augment Activity of Chemotherapy in Advanced Urothelial Carcinoma?
Low-Grade Bladder Cancer: Can Mitomycin-Based Chemoablation Reduce the Need for Surgery?
Can Urothelial Bladder Carcinoma Cause Chronic Knee Problems?
Case Report: Older Woman With Metastatic Bladder Cancer Responds to Pembrolizumab
Laser Versus Electrical En Bloc Resection of Bladder Tumors
CheckMate 274: Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma
Are Lebanese and Jordanian Populations at Higher Risk for Bladder Cancer?
Enfortumab Vedotin-ejfv Under Study in Cisplatin-Ineligible Urothelial Carcinoma
Rare Case of Bladder Metastasis of Kidney Cancer: Potential Role of Genomic Analysis
Bacillus Calmette-Guérin Therapy for Bladder Cancer and Likelihood of COVID-19 Infection
Feasibility Study in Upper Tract Urothelial Cancer: Neoadjuvant Pembrolizumab Before Surgery
Impact of COVID-19 on Cystoscopic Surveillance for Non–Muscle-Invasive Bladder Cancer
Treatment Patterns and Outcomes in Muscle-Invasive Bladder Cancer
Combination Therapy for Metastatic Urothelial Bladder Carcinoma With FGFR3 Mutation: A Case Study
Identifying Bladder Cancer Subtypes by Metabolic Characteristics: Therapeutic Implications
STAG2 Immunostaining: Potential Biomarker in Predicting Bladder Cancer Outcomes?
Adjuvant Nivolumab for Patients With High-Risk Muscle-Invasive Urothelial Carcinoma
Camrelizumab Treatment in Upper Tract Urothelial Carcinoma: Case Report
Hypoxia-Related Gene Signature: An Independent Clinical Predictor in Bladder Cancer?
Mixed Results With Rucaparib in ATLAS Trial in Metastatic Urothelial Cancer
CALGB 90601: Combination Gemcitabine and Cisplatin With Bevacizumab in Urothelial Carcinoma
Resistant Urothelial Carcinoma: Organ-Specific Response to Pembrolizumab
The Hormone Ghrelin: Potential Prognostic Predictor in Muscle-Invasive Bladder Cancer?
Rare Complication of Intravesical BCG Therapy for Bladder Cancer: Case Report
Is Dietary Acrylamide Intake Associated With the Development of Bladder Cancer?
Does a Family History of Any Cancer Increase the Risk for Bladder Cancer?
Do Men and Women With Urinary Bladder Cancer Respond Differently to BCG Immunotherapy?
Can Treatment-Specific COXEN Scores Predict Responses to Neoadjuvant Chemotherapy for Bladder Cancer?
Diagnostic Utility of Serum N‐glycan Profiles in Urothelial Carcinomas
TP53-Mutated Bladder Cancer: Identifying Patients Who May Benefit From Immunotherapy
Does Use of Aspirin Improve Outcomes in Older Adults With Bladder Cancer?
Prescription of Psychotropic Drugs in Older Patients With Bladder Cancer
Low-Dose BCG Tokyo Strain for Non–Muscle-Invasive Bladder Cancer
Unleashing the Therapeutic Potential of Natural Compounds Against Bladder Cancer
Systemic Treatment of Metastatic Bladder Cancer: Dutch Study of Current Clinical Practice
Radical Cystectomy Versus BCG Treatment for High-Risk Bladder Cancer
Novel Prognostic Biomarker for Bladder Cancer Investigated
Immunotherapy for Urothelial Cancer: Balancing Benefits and Risks
Preferred Treatment for Invasive Bladder Cancer: Intravesical Immunotherapy or Radical Cystectomy?
Measures of Tumor Heterogeneity: Useful Biomarkers of Bladder Carcinoma?
Study Identifies Potential Biomarker of Bladder Carcinoma Recurrence
Impact of Preoperative Positive Voided Urine Cytology on Prognosis in Urothelial Cancer
Intravesical Nadofaragene Firadenovec in Non–Muscle Invasive Bladder Cancer
Ramucirumab Plus Docetaxel in Urothelial Carcinoma: Patient-Reported Outcomes From RANGE Trial
Pelvic Radiotherapy Combined With Chemotherapy in Metastatic Urothelial Cancer
Predicting Risk of Recurrence in Nonmuscle‐Invasive Bladder Cancer
Preoperative Chemotherapy for High-Grade Upper Tract Urothelial Carcinoma
Nab-paclitaxel Versus Paclitaxel in Metastatic Urothelial Cancer
Surveillance Strategy for Patients With Upper Tract Urothelial Carcinoma
Dose-Dense Chemotherapy for Muscle-Invasive Bladder Cancer: Phase III Trial Toxicity Update
Case Study: Neoadjuvant Pembrolizumab in Chemoresistant Urothelial Carcinoma
Targeting Bladder Carcinoma in Situ With Novel Gene Therapy
After Surgery for Upper Urinary Tract Urothelial Carcinoma: Surveillance or Chemotherapy?
Potential Genomic Predictors of Outcomes in High-Grade T1 Bladder Cancer
DANUBE Trial: Survival Outcomes With Durvalumab in Advanced Urothelial Carcinoma
Combination Regimen Under Study in Metastatic Urothelial Carcinoma
Update on Managing Non–Muscle-Invasive Bladder Cancer
Can Leukocyte Telomere Length Predict Bladder Cancer Risk?
Bladder Urothelial Carcinoma: Is Age Related to Risk of Lymph Node Metastasis?
Early Results With Buparlisib in Treatment of Metastatic Urothelial Carcinoma
Testicular Tuberculosis: Case Study of Rare Complication of Urothelial Cancer Treatment
Perioperative Chemotherapy for High‐Risk Upper Tract Urothelial Carcinoma
Early Findings With Magnetic Resonance–Guided Radiotherapy for Bladder Cancer


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.